Your browser doesn't support javascript.
Real world utilization of REGEN-COV2 at a community hospital.
Ash, Jordan; Leavitt, Rachael; Dietrich, Tyson; Schritter, Sarah; Wells, James; Santarelli, Anthony; Ashurst, John.
  • Ash J; Arizona College of Osteopathic Medicine, USA.
  • Leavitt R; Rocky Vista University College of Osteopathic Medicine, USA.
  • Dietrich T; Department of Pharmacy, Kingman Regional Medical Center, USA. Electronic address: TDietrich@azkrmc.com.
  • Schritter S; Department of Nursing, Kingman Regional Medical Center, USA. Electronic address: SSchritter@azkrmc.com.
  • Wells J; Department of Nursing, Kingman Regional Medical Center, USA. Electronic address: James.Wells@azkrmc.com.
  • Santarelli A; Department of Graduate Medical Education, Kingman Regional Medical Center, USA. Electronic address: Anthony.Santarelli@azkrmc.com.
  • Ashurst J; Department of Emergency Medicine, Kingman Regional Medical Center, USA. Electronic address: Ashurst.john.32.research@gmail.com.
Am J Emerg Med ; 50: 129-131, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1330533
ABSTRACT

INTRODUCTION:

Monoclonal antibodies received an Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration for the outpatient treatment of mild to moderate coronavirus disease 2019 (COVID-19). REGN-COV2, casirivimab and imdevimab, has been shown to decrease the viral load and healthcare visits of those with mild to moderate COVID-19 who are treated in the outpatient setting.

OBJECTIVE:

To determine 7- and 14-day emergency department (ED) and hospitalization rates of adult patients given REGN-COV2 for the outpatient treatment of COVID-19 at a community hospital.

METHODS:

A convenience sample of consecutive adult patients given REGN-COV2 from January 18, 2021 through March 31, 2021 for the outpatient treatment of mild to moderate COVID-19. Abstracted data included patient demographics, allergic reactions, ED presentations and hospitalizations at 7 and 14 days, and in-hospital mortality.

RESULTS:

A total of 68 patients with a medain age of 69 years (IQR 57-75.5) and 58.3% being female were given REGEN-COV2 during the study period. No allergic reactions were noted during infusion. Of those infused, 18% (12/68) were infused in the ED and had a median length of stay of 477 min. Following infusion, 10% (7/68) of patients re-presented to the ED and 2% (1/68) were hospitalized for COVID-19 at 14 days. In those aged 65 years or greater, 12% (5/42) of patients re-presented to the ED following infusion. Of those who re-presented to the emergency department, the median age was 72.5 years and the median time from infusion to re-presentation was 2.0 days. No patients suffered in-hospital mortality during the study period.

CONCLUSION:

There was a significant length of stay associated with REGN-COV2 infusion in the emergency department. Following REGN-COV2 infusion, few patients under the age of 65 re-presented to the emergency department at seven and 14 days. However, a large number of patients aged over 65 years re-presented to the ED following infusion.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Emergency Service, Hospital / Antibodies, Neutralizing / Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment / Hospitals, Community Type of study: Cohort study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Am J Emerg Med Year: 2021 Document Type: Article Affiliation country: J.ajem.2021.07.050

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Emergency Service, Hospital / Antibodies, Neutralizing / Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment / Hospitals, Community Type of study: Cohort study / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Am J Emerg Med Year: 2021 Document Type: Article Affiliation country: J.ajem.2021.07.050